Clinical Efficacy of Belight3TM on Dark Spot Pigmentation in Caucasian Subjects

Belight3TM, a nutricosmetic formulation containing polyphenol-rich extracts, has previously been demonstrated to be safe and effective in brightening skin color and dark spots in a clinical study involving Asian volunteers. The aim of this study was to investigate the efficacy of this formulation in lightening dark spots in a Caucasian population, which is characterized by lighter skin pigmentation and greater visibility of hyperpigmentation, as well as to determine whether the supplementation increased sensitivity to UV exposure. A randomized, double-blind, placebo-controlled clinical study was conducted on 66 male and female participants with skin phototype I to III, all exhibiting facial hyperpigmentation. The color of selected dark spots was assessed using spectrophotometry to measure the L* value of the CIELab color space and the Individual Typology Angle (ITA). L* and ITA levels of dark spots were significantly increased after 6 and 12 weeks of Belight3TM treatment (respectively by +1.2% and +2.5% for L* and by 12.1% and 22.5% for ITA), and this lightening effect was significantly higher than the placebo after 12 weeks (p < 0.05 for L*; p < 0.001 for ITA). Clinical evaluation of skin complexion evenness and dark spot visibility were also improved in subjects receiving the Belight3TM treatment, achieving a significant difference with the placebo after 12 weeks. No changes in MED or skin redness were observed during this study. This study confirmed the safety and efficacy of Belight3TM in lightening dark spots in a Caucasian population without increasing UV sensitivity.